Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Queensland Health
Chinese Patent Office
Daiichi Sankyo
Healthtrust
Colorcon
Teva
Express Scripts
Novartis

Generated: August 23, 2017

DrugPatentWatch Database Preview

Us Worldmeds Company Profile

« Back to Dashboard

What is the competitive landscape for US WORLDMEDS, and when can generic versions of US WORLDMEDS drugs launch?

US WORLDMEDS has five approved drugs.

There are three US patents protecting US WORLDMEDS drugs.

There are seventy-six patent family members on US WORLDMEDS drugs in thirty-one countries.

Summary for Applicant: Us Worldmeds

Patents:3
Tradenames:5
Ingredients:5
NDAs:5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Worldmeds Llc
XADAGO
safinamide mesylate
TABLET;ORAL207145-001Mar 21, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Us Worldmeds
APOKYN
apomorphine hydrochloride
INJECTABLE;SUBCUTANEOUS021264-002Apr 20, 2004RXYesYes► Subscribe► Subscribe► Subscribe
Us Worldmeds Llc
CORGARD
nadolol
TABLET;ORAL018063-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Us Worldmeds Llc
CORGARD
nadolol
TABLET;ORAL018063-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Us Worldmeds
REVONTO
dantrolene sodium
INJECTABLE;INJECTION078378-001Jul 24, 2007APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Us Worldmeds

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Worldmeds Llc
CORGARD
nadolol
TABLET;ORAL018063-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Worldmeds Llc
CORGARD
nadolol
TABLET;ORAL018063-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Worldmeds Llc
CORGARD
nadolol
TABLET;ORAL018063-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Worldmeds Llc
ZELNORM
tegaserod maleate
TABLET;ORAL021200-001Jul 24, 2002► Subscribe► Subscribe
Us Worldmeds Llc
CORGARD
nadolol
TABLET;ORAL018063-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Us Worldmeds

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,901,176Methods for treatment of Parkinson's disease► Subscribe
9,492,410Methods for treatment of Parkinson's disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Us Worldmeds Drugs

Country Document Number Estimated Expiration
Germany602004021790► Subscribe
Serbia53824► Subscribe
Portugal2029524► Subscribe
BrazilPI0409364► Subscribe
Russian Federation2342929► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Us Worldmeds Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00042Denmark► SubscribePRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224
782Luxembourg► SubscribePRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
/2015Austria► SubscribePRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
1 50017-2015Slovakia► SubscribePRODUCT NAME: SAFINAMID; REGISTRATION NO/DATE: EU/1/14/984/001 - EU/1/14/984/010 20150226
0505322/01Switzerland► SubscribePRODUCT NAME: TEGASEROD; REGISTRATION NO/DATE:IKS 55689 20011030
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Fish and Richardson
Harvard Business School
Chinese Patent Office
Cipla
Federal Trade Commission
Colorcon
Accenture
Healthtrust
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot